GlassScriptPhysician profile
David A Graham
NPI 1306931068
$4,752.29
in general payments reported to CMS, 2019-2025
29 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544 · 2020: $825 · 2021: $1,301 · 2022: $1,294 · 2023: $688 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $654.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $556.02 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $495.48 | 2019-2023 | |
| Amgen INC. | $431.19 | 2019-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.14 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $381.25 | 2019-2023 | Verquvo |
| Amarin Pharma, INC. | $334.43 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $333.54 | 2019-2022 | |
| Esperion Therapeutics, INC. | $322.91 | 2020-2023 | Nexletol |
| Astellas Pharma US INC | $256.93 | 2019-2020 | |
| Pfizer INC. | $237.81 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $188.87 | 2020-2023 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $161.14 | 2019-2023 | Lifevest |
| Novo Nordisk INC | $118.88 | 2020-2022 | |
| Telix Pharmaceuticals | $100.00 | 2025 | Illuccix |
| Boston Scientific Corporation | $47.09 | 2022-2023 | Watchman Access System |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $34.13 | 2019-2020 | |
| Dynavax Technologies Corporation | $22.40 | 2021 | |
| Exact Sciences Corporation | $21.17 | 2023 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $19.33 | 2019 | |
| Amryt Pharma Holdings LTD | $18.11 | 2021 | |
| Abiomed | $17.86 | 2023 | Impella |
| Abbott Laboratories | $17.54 | 2020 | |
| Scpharmaceuticals INC. | $16.03 | 2023 | |
| Edwards Lifesciences Corporation | $15.38 | 2019 | |
| Glaxosmithkline, LLC. | $15.00 | 2022 | |
| Irhythm Technologies, INC. | $14.49 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.41 | 2022 | |
| Medtronic, INC. | $12.44 | 2021 | |
| Penumbra, INC. | $11.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.